Skip to main content

Table 1 Baseline characteristics of study cohort (n = 132)

From: Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Characteristic

Entire cohort (n = 132)

CC-CCD, mg/m2

P valuea

< 160 (n = 52, %)

≥ 160 (n = 80, %)

Sex

0.354

 Male

92 (69.7)

39 (75.0)

53 (66.2)

 

 Female

40 (30.3)

13 (25.0)

27 (33.8)

 

Age, years

0.494

 ≤ 15

69 (52.3)

25 (48.1)

44 (55.0)

 

 < 15

63 (47.7)

27 (51.9)

36 (45.0)

 

Smoking history

0.170

 No

123 (93.2)

46 (88.5)

77 (96.2)

 

 Yes

9 (6.8)

6 (11.5)

3 (3.8)

 

BMI, m2

0.310

 ≤ 1.45

64 (48.5)

22 (42.3)

42 (52.5)

 

 > 1.45

68 (51.5)

30 (57.7)

38 (47.5)

 

EBV DNA, copy/mL

0.293

 < 4000

52 (39.4)

17 (32.7)

35 (43.7)

 

 ≥ 4000

80 (60.6)

35 (67.3)

45 (56.3)

 

T stageb

0.281

 T1

1 (0.8)

1 (1.9)

0 (0)

 

 T2

4 (3.0)

1 (1.9)

3 (3.8)

 

 T3

59 (44.7)

27 (51.9)

32 (40.0)

 

 T4

68 (51.5)

23 (44.2)

45 (56.3)

 

N stageb

0.165

 N0

1 (0.8)

1 (1.9)

0 (0)

 

 N1

18 (13.6)

8 (15.4)

10 (12.5)

 

 N2

65 (49.2)

29 (55.8)

36 (45.0)

 

 N3

48 (36.4)

14 (26.9)

34 (42.5)

 

Overall stageb

0.114

 III

36 (27.3)

19 (36.5)

17 (21.3)

 

 IVA

48 (36.4)

19 (36.5)

29 (36.2)

 

 IVB

48 (36.4)

14 (26.9)

34 (42.5)

 

NAC cycles

0.062

 2

60 (45.5)

30 (57.7)

30 (37.5)

 

 3

66 (50.0)

21 (40.4)

45 (56.3)

 

 4

6 (4.5)

1 (1.9)

5 (6.2)

 

NAC regimens

< 0.001

 TPF

73 (55.3)

18 (34.6)

55 (68.8)

 

 TP

20 (15.2)

13 (25.0)

7 (8.8)

 

 PF

35 (26.5)

21 (40.4)

14 (17.5)

 

 GP

4 (3.0)

0 (0.00)

4 (5.0)

 

Adjuvant chemotherapy

0.575

 No

129 (97.7)

50 (96.1)

79 (98.7)

 

 Yes

3 (2.3)

2 (3.9)

1 (1.3)

 

NAC-CCD, mg/m2

0.112

 < 180

62 (47.0)

29 (55.8)

33 (41.3)

 

 ≥ 180

70 (53.0)

23 (44.2)

47 (58.7)

 

Radiation dose, cGy

0.386

 < 6800

64 (49.6)

22 (44.0)

42 (53.2)

 

 ≥ 6800

65 (50.4)

28 (56.0)

37 (46.8)

 
  1. CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy, BMI body mass index, EBV Epstein–Barr virus, NAC neoadjuvant chemotherapy, TPF cisplatin with 5-fluorouracil and toxoids, TP cisplatin with toxoids, PF cisplatin with 5-fluorouracil, GP cisplatin with gemcitabine, NAC-CCD cumulative cisplatin dose during neoadjuvant chemotherapy
  2. aP values were calculated using the chi-square test or Fisher exact test if indicated
  3. bAccording to the 7th edition of the Union for International Cancer Control/American Joint Committee on Cancer staging system